secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001193125-25-173985
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Q2 net loss narrows to $19.9M; CEO replaced; SER-155 Phase 2 protocol filed
--------------------------------------------------------------------------------

- Net loss from continuing ops $19.9M in Q2 2025 vs $26.2M in Q2 2024; cash $45.4M as of June 30.
- Received $25M Nestlé installment in July; expects cash runway into Q1 2026.
- Co-CEOs Thomas DesRosier and Marella Thorell appointed Aug 1 after prior CEO Eric Shaff departed.
- SER-155 Phase 2 protocol submitted to FDA for BSI prevention in allo-HSCT; awaiting FDA feedback.
- Engaging with multiple parties on partnerships, out-licensing, or mergers to secure capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525173985/0001193125-25-173985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525173985/d930624d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-173985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer